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Background: Despite evidence implicating dietary sodium in the pathogenesis of cardiovascular disease (CVD) in
chronic kidney disease (CKD), quality intervention trials in CKD patients are lacking. This study aims to investigate
the effect of reducing sodium intake on blood pressure, risk factors for progression of CKD and other cardiovascular
risk factors in CKD.
Methods/design: The LowSALT CKD study is a six week randomized-crossover trial assessing the effect of a
moderate (180 mmol/day) compared with a low (60 mmol/day) sodium intake on cardiovascular risk factors and
risk factors for kidney function decline in mild-moderate CKD (stage III-IV). The primary outcome of interest is
24-hour ambulatory blood pressure, with secondary outcomes including arterial stiffness (pulse wave velocity),
proteinuria and fluid status. The randomized crossover trial (Phase 1) is supported by an ancillary trial (Phase 2) of
longitudinal-observational design to assess the longer term effectiveness of sodium restriction. Phase 2 will
continue measurement of outcomes as per Phase 1, with the addition of patient-centered outcomes, such as
dietary adherence to sodium restriction (degree of adherence and barriers/enablers), quality of life and taste
assessment.
Discussion: The LowSALT CKD study is an investigator-initiated study specifically designed to assess the
proof-of-concept and efficacy of sodium restriction in patients with established CKD. Phase 2 will assess the longer
term effectiveness of sodium restriction in the same participants, enhancing the translation of Phase 1 results into
practice. This trial will provide much-needed insight into sodium restriction as a treatment option to reduce risk of
CVD and CKD progression in CKD patients.
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ACTRN12611001097932
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Cardiovascular disease (CVD) is the leading cause of
mortality in the chronic kidney disease (CKD) popula-
tion, with CKD patients being 5–10 times more likely to
die of CVD than to progress to end-stage kidney disease
(ESKD) [1,2]. Dietary sodium intake has been associated
with numerous modifiable risk factors for CVD in CKD
including increased blood pressure (BP), volume over-
load, left ventricular hypertrophy, inflammation and
endothelial damage [3-6] (Figure 1). Indicators of kidney
damage, proteinuria and albuminuria have also been
associated with sodium intake [6,7], and are key risk fac-
tors for subsequent all-cause and cardiovascular mortal-
ity [8,9]. However, despite evidence implicating dietary
sodium in the pathogenesis of CVD in CKD, quality
intervention trials in CKD patients are lacking.
Several meta-analyses of dietary sodium intake and
blood pressure (BP) have been published, consistently
demonstrating that a reduction in dietary sodium intake
leads to reduced BP, particularly in hypertensive popula-
tions [10-14]. Unfortunately most studies included in
these analyses exclude patients with kidney disease.
Since sodium balance is primarily the role of the kidney,
it is highly likely that CKD patients have a reduced abil-
ity to excrete the high sodium intake that is typical of a
Western diet, increasing susceptibility to the adverse
effects of excessive dietary sodium [15,16]. This may par-
tially explain why hypertension is so prevalent in CKD,
with data indicating that up to 70% of CKD patients are
hypertensive [17].
An issue with translation of research in sodium restric-
tion into practice is poor dietary adherence. This has
been reported in several research trials [18-21]. Further-
more, data indicate approximately 80-90% of CKD
patients consume more than 100 mmol of sodium per
day [19-21], meaning that most do not adhere to the tar-
get set by evidence-based practice guidelines [22-26].
Achieving sodium restriction can be difficult in researchFigure 1 Simplified diagram of the relationship between excess sodiu
by decreased sodium excretion & high sodium intake (*influenced by food
increases cardiovascular risk not only via altered extracellular volume & bloand in practice. Therefore, it is vitally important to es-
tablish the feasibility of achieving adherence to sodium
restriction in the clinical setting, as well as exploring the
efficacy of this intervention.
Dietary sodium shows great promise as a modifiable
risk factor for reduction of cardiovascular risk and risk
of renal function decline in CKD, but high quality evi-
dence is lacking. There is a need for a research trial
showing the efficacy of sodium restriction for reducing
the risks of CVD and CKD progression in CKD. Further,
the effectiveness of recommendations to restrict sodium




The aim of the LowSALT CKD study is to examine the im-
pact of reducing dietary sodium intake in decreasing car-
diovascular risk in CKD patients. Our primary hypothesis
is that a low sodium intake (LSI) (60 mmol/day) in patients
with stage III or IV CKD will be independently associated
with decreased ambulatory BP compared to a moderate
sodium intake (MSI) (180 mmol/day). Our secondary
hypothesis is that LSI (60 mmol/day) will result in the fol-
lowing outcomes compared with MSI (180 mmol/day):
decreased arterial stiffness; decreased proteinuria and albu-
minuria; decreased extracellular fluid and markers of vol-
ume overload and thirst.
Study design and setting
The LowSALT CKD study is a single-centre double-blind
randomized cross-over trial (Phase 1) with a prospective
observational follow-up (Phase 2). Phase 1 entails a 7-day
run-in period followed by two, 2-week interventions
(Figure 2). Participants follow a low sodium diet (goal: 60
mmol/day) together with either moderate sodium intake
(achieved via slow-release sodium tablets providing 120
mmol sodium/day) or placebo (low sodium intake) form, kidney damage and risk of CVD. Excess sodium in CKD is caused
supply and preference – potentially mediated by taste sensitivity). This
od pressure (BP) but also through direct toxic effects on blood vessels.
Figure 2 LowSALT CKD study flowchart.
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tion with a 1-week washout in between (Figure 2).
These levels of sodium intake represent two extremes
of typical sodium intake in the Western diet, with the
moderate sodium target (180 mmol sodium/day) repre-
senting that found in observational studies [19,27,28]
and the low sodium target (60 mmol/day) resembling a
level that meets even the strictest evidence-based prac-
tice guidelines specific to CKD [29]. Phase 2 involves a
further 20-week observational period, where partici-
pants will be encouraged to adhere to a low sodium
diet, and outcome measures repeated at 4 and 6
months (after commencement of Phase 1).
Ethical considerations
Ethical approval has been obtained through Metro South
Human Research Ethics Committee and University of
Queensland Human Research Ethics Committee.
Target population and eligibility criteria
The target population for the trial will be stage III and
IV non-dialyzed CKD patients. Eligibility criteria will in-
clude hypertensive, CKD stage III or IV (GFR 15–59 ml/
min/1.73 m2) non-dialyzed, non-transplanted patients
under the care of a nephrologist at the Princess Alexan-
dra Hospital; aged ≥ 18 years with systolic BP 130–169
mmHg and diastolic BP ≥ 70 mmHg; non salt-wasting
CKD (as diagnosed by nephrologist); prescribed ≤ 20
mmol sodium per day via medications; not pregnant or
breastfeeding; life expectancy > 6 months; no current in-
volvement in other intervention study and mental cap-
acity to adhere to the study protocol (as indicated by
medical team).
Recruitment of participants
Potential participants will be identified through the out-
patient clinic lists at the Princess Alexandra Hospital
(PAH). To confirm that a potential participant’s bloodpressure is within range, BP will be measured once in
seated position when the participant attends clinic and
previous BPs will be collected from the medical notes.
Once a potential trial participant has been screened as
meeting the eligibility criteria, recruitment by informed
consent will be sought either at the time of the clinic
visit or at a later date (providing additional time to con-
sider the information). Once consented, patients will
undergo 24-hour ambulatory blood pressure (ABP)
measurement at baseline to confirm eligibility. Patients
with 24-hour BP ≤ 130/70 will be discontinued from the
study due to the potential risk of hypotension with so-
dium reduction. Patients and the treating doctors will be
asked to keep the anti-hypertensive medications un-
changed for the duration of the trial within bounds of
patient safety.
Dietary counseling
All patients will be counseled to follow a low sodium diet
for the entire trial duration. Initial dietary education will
occur face-to-face during run-in, with ongoing education
during follow up visits and phone calls (Table 1). Topics
covered will include: target sodium intake, general guide-
lines for following a low sodium diet, reading labels, foods
and drinks high in sodium and lower sodium alternatives
(individualized to participant’s usual dietary habits), low
salt cooking methods and recipe ideas. In addition, partici-
pants will be provided with written dietary education
materials (based on established resources used in CKD
and heart failure patients to reduce sodium intake
[30,31]). During Phase 1, participants will also be provided
with a selection of low sodium foods to facilitate adher-
ence to a low sodium diet (Table 1).
Randomization
An external statistical consultant will undertake the
computer-generated randomization for the order of the
intervention in blocks of 8, blinded to the investigators.
Table 1 Strategies to facilitate sodium restriction
Phase 1 - Dietary education (individualized) by accredited practicing dietitian
- Focus on replacing high sodium foods with low sodium alternatives (keeping energy intake stable).
- Initial education in run-in with written materials provided
- Ongoing education during follow up visits and weekly phone calls.
- Partial food provision
- Low sodium frozen pre-prepared meals (maximum 1 per day)
- Snack foods, breakfast cereal, cheese and bread
Phase 2 - Ongoing dietary education
- Monthly via phone calls
- No food provided in this phase
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to the treatment, study medications are packaged off-site
by an external pharmacy with a generic label as medica-
tion 1 and 2 for the first and second intervention.
Intervention
As per Figure 2, following a 7 day run-in period, partici-
pants will enter ‘treatment’ (moderate sodium arm, 180
mmol/day) or ‘control’ (low sodium arm, 60 mmol/day)
for 2 weeks duration and cross-over to the alternate
treatment. During ‘treatment’ participants will receive
120 mmol sodium /day via slow-release sodium chloride
tablets (4 × 10 mmol tablets t.d.s; Slow Sodium, Novartis
Pharmaceuticals Australia Pty Ltd), in addition to 60
mmol dietary intake. During ‘control’, participants will
receive white placebo capsules (4 × capsules t.d.s, size
1D cellulose capsules, Pharmaceutical Packaging Profes-
sionals Pty Ltd). A washout period (1 week duration)
will precede intervention two; this period was chosen as
previous research indicated this is the duration needed
to achieve sodium balance [32]. During washout, partici-
pants will continue to consume a low sodium diet (goal
60 mmol/day).
Primary outcome - ambulatory blood pressure
24-hour ABP was selected as the primary outcome as it
is the most accurate reflection of BP, with measurements
over an entire 24-hour period indicating diurnal vari-
ation, while avoiding error due to white-coat or masked
hypertension [33-35]. Data will be measured at time
points as per Figure 2 and will be analyzed as mean
24-hour BP, daytime BP and night BP.
ABP will be measured using the TM-2430 Ambulatory
Blood Pressure Monitor (A&D Medical, Australia). This
device is a non-invasive lightweight portable device that
is validated in accordance with British Hypertension So-
ciety protocol, with A/A rating [36]. ABP measurements
will be conducted according to the ‘Practice Guidelines
of the European Society of Hypertension’ for clinic, am-
bulatory and self BP measurement [33] with systolic anddiastolic BP recorded every 20 minutes during the day (6
AM to 10 PM) and 30 minutes at night (10 PM to 6
AM) [33,37,38]. The left arm will be used for measure-
ment, except when medical history indicates an existing
claudication. The measurement arm will be kept consist-
ent during the study. ABP monitoring will be considered
adequate if at least two-thirds of the measurements
taken over the 24-hour period are satisfactory [33]. Par-
ticipants will be trained on the use of the 24-hour BP
monitor when they attend the clinic to have measure-
ments taken, and will be asked to record their sleep and
wake times during the BP monitoring period. Investiga-
tors and patients will be blinded to ABP results.
Secondary outcome
Arterial stiffness
Arterial stiffness will be assessed by carotid-femoral Pulse
Wave Velocity (PWV), which is the current gold standard
for non-invasive measurement of aortic arterial stiffness
[39], and by radial Pulse Wave Analysis (PWA), which
derives the augmentation of the central pulse waveform
via measurement at the peripheral (radial) artery. Both
measurements will be taken with SphygmoCor™ CPV
(AtCor Medical) which employs applanation tonometry to
measure the shape and velocity of the pulse wave, with
good repeatability and reproducibility [40].
To ensure accuracy and reproducibility, measurements
will be taken in the morning after fasting blood samples.
Participants will be provided with a standardized breakfast
(breakfast cereal and/or muesli bars) and will be asked to
abstain from tobacco and caffeine at least 4 hours before
the measurement. PWV will be assessed by measuring
carotid and femoral artery wave-forms sequentially over
the common carotid and femoral arteries. Radial PWA
will be used to estimate central pulse pressure and aug-
mentation index. Both PWV and PWA measurements will
be measured in duplicate. Validity of the measurements
will be assessed as per the SphygmoCor manual [41], with
an operator index of >80 indicating a good quality meas-
urement for PWA and a standard error <10% of the PWV
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Where significant disagreements between the measure-
ments exist, the measurement will be repeated until mea-
surements within 10% of each other are obtained.
Urinary protein and albumin
24-hour urine samples (gold standard for measuring
proteinuria and albuminuria) [42] will be used in this
trial. Participants will be provided with bottles for collec-
tion and educated on correct collection procedure in ac-
cordance with standard protocol. Storage and processing
of the urine samples will also be carried out according
to standard protocol. Both participants and investigators
will be blinded to the urinary results.
Fluid status
Fluid status, a predictor of cardiac alterations such as left
ventricular hypertrophy [3], will be indicated by bio-
impedance spectroscopy (BIS). This will be assessed by
the Body Composition Monitor (BCM) (Fresenius Medical
Care, Germany), which determines total body and extra-
cellular water by measuring electrical resistance across 50
frequencies using electrodes placed on the wrist & foot,
(5 to 1000 kHz) [43,44]. BIS is a quick, non-invasive
method to assess fluid status, validated against gold stand-
ard dilution methods [45]. The BCM has been shown to
be an accurate indicator of fluid change when compared
to body weight before and after dialysis sessions in haemo-
dialysis patients [44]. Measurements will be performed in
accordance with the manufacturer’s instructions [46].
Patients with stents or pacemakers will be excluded from
this assessment. Participants and investigators will be
blinded to the BIS results.
Secondary outcome - xerostomia index (thirst)
Thirst will be measured by the Xerostomia Index (XI) [47-49].
The XI is a score summated a subjective 11 item ques-
tionnaire [47] measuring the severity of the symptoms
of dry mouth across one of five responses (‘never’, scor-
ing 1; ‘hardly ever’, 2; ‘occasionally’, 3; ‘fairly often’, 4;
and ‘very often’, 5)’. Each individual’s responses will be
scored and summated to give a single XI score [47].
Secondary outcomes: serum metabolic markers
Serum blood samples will be stored for analysis of markers
of inflammation (CRP), adiponectin (total and high molecu-
lar weight), markers of renin-angiotensin-aldosterone system
stimulation (renin, aldosterone, angiotensin-converting-
enzyme) and a marker of fluid overload (NT-proBNP) in
addition to the standard tests taken in practice (e.g. full
blood count and urea and electrolytes). Blood samples
will be collected after overnight fast and drawn from a per-
ipheral vein while participants are seated. Blood will be cen-
trifuged within 30 minutes after blood collection. Afterseparation, plasma will be transferred using a graduated
plastic disposable pipette into color coded storage vials and
placed in freezer storage boxes in a −80°C freezer. Add-
itional serum will be stored for the analysis of novel risk fac-
tors in the future. Participants and investigators will be
blinded to the serum outcomes.
Adherence/dietary intake measures
A multi-method approach to measuring dietary sodium
intake was chosen to employ both objective and self-
reported methods, optimizing accuracy of dietary intake
estimation, while minimizing participant burden [50].
The current gold standard for dietary sodium intake
measurement is repeated 24-hour urinary sodium excre-
tion [51,52]. Due to the increased participant burden
involved in 24-hour urine collection, 24 hr collections
(at baseline and all follow up points) will be supplemen-
ted with mid-stream urine collections occurring weekly
in Phase 1 and at follow up points in Phase 2 (see Figure 2).
Mid-stream urinary sodium has recently been demon-
strated to have good agreement with 24-hour urinary
sodium in CKD [53,54], and the collection of 24-hour
samples concurrently with mid-stream samples will
allow for further exploration of the agreement between
these measures. Mid-stream urine samples will be ana-
lyzed for sodium, creatinine and albumin concentra-
tions (Figure 3).
In addition to objective measures, a diet history and
food frequency questionnaire (FFQ) will be used to
measure dietary intake. In the diet history method, infor-
mation about what is consumed over an extended period
of time is collected using open-ended questions [55].
This is considered an ideal method for capturing ‘usual
intake’ over a specified period of time [56]. To minimize
the time burden and participant recall bias, which typic-
ally limit the use of the diet history, this trial will use a
self-administered diet history (Wollongong method [56])
with forms mailed to participants in advance and verified
by a dietitian interview. The FFQ, which is designed spe-
cifically to quantify sodium intake [52], will also be
mailed with the diet history. Participants will complete
these forms at home and bring them to their appoint-
ment where information will be verified by the study
dietitian using food models and visual prompts to quan-
tify intakes. Dietary histories will be entered into Food-
Works 7 (Xyris Software, Version 7.0.2915) using the
Nuttab 2010 database (for general unbranded foods and
known recipes), AusBrands 2012 database (where spe-
cific brand is known) and AusFoods 2012 (for conveni-
ence or pre-prepared foods where recipe is unknown).
The FFQ will be scored as per Charlton protocol [52].
The final method for measuring intake will be a daily
checklist, used throughout the entire 6 weeks of Phase
1. This is designed to capture intake of foods likely to
Figure 3 LowSALT CKD study data collection schedule.
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data of CKD patients at the PAH, (Longitudinal Assess-
ment of Multiple Discrete Atherosclerotic Risk factors
in Kidney Disease (Landmark) Study, Isbel N et al.), as
well as daily record of study medication. The informa-
tion on this checklist will be verified for completeness
and accuracy. Adherence to the study medication will
also be measured by pill count at trial end. Medication
changes will be recorded, with all efforts made to avoid
change of anti-hypertensive medications during the six
week trial.
Phase 2
Phase 2 of the trial (observational arm to 6 months after
baseline visit) aims to assess long-term changes in out-
comes and adherence to a sodium-restricted diet, as well
as establishing common barriers and enablers to achieving
dietary sodium restriction in this group. In this phase, bar-
riers and enablers to adherence will be measured via four
self-administered questionnaires. Self-efficacy will be mea-
sured using the health-related general self-efficacy scale
[57] and health-related locus of control using the Multidi-
mensional Health Locus of Control [58]. Beliefs about
dietary compliance scale (BDCS) [59] and attitudes to diet-
ary recommendations scale (ADRS) (modified from [60])
will be assessed. Results from the locus of control and
self-efficacy scales will be used to identify predictors ofdietary adherence. Results from the beliefs about dietary
compliance (BDSC) will be used to identify specific bar-
riers and enablers to dietary adherence. Results from the
attitudes to dietary recommendations (ADRS) will assist
in identifying specific recommendations with which parti-
cipants find it difficult to adhere.
Another outcome specific to Phase 2 is taste assess-
ment of the five basic taste senses: salty, sweet, bitter,
sour and umami. Evidence suggests that hedonic liking
and taste sensitivity of salty taste can be modified with
adherence to a low sodium diet [61], however this is yet
to be established in the CKD population. A further gap
in the literature is whether restriction of dietary sodium
could affect the other four taste senses; (sweet, bitter,
sour and umami). In accordance with the International
Standards Organization method of investigating sensitiv-
ity of taste [62], participants will be presented with 2 ml
solutions of substances which represent each of the five
basic taste qualities (and which are found ubiquitously
throughout the food supply) and asked to identify each
taste as well as the strength of the taste on a 10-cm vis-
ual analogue scale. This enables assessment of ability to
detect each taste and the degree of sensitivity, measured
at baseline and phase 2 follow up visits (Figure 2).
CKD patients have been found to have significantly
decreased quality of life (QoL) with QoL decreasing as
GFR declines [63]. Hypertensive patients have also been
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normotensives [63]. Restricted sodium intake may in-
crease quality of life by reducing symptoms associated
with fluid overload, such as sleep apnea and edema.
Therefore, quality of life (QoL) will be assessed by the
Short Form-36.
Overall, Phase 2 aims to translate the promising indi-
cations from basic science into clinical practice demon-
strating the effect of dietary sodium on blood pressure,
risk factors for CKD progression and cardiovascular
disease.
Statistical analysis
The primary outcome will be change in 24-hour SBP
from matched pairs of study subjects (by cross-over de-
sign) from MSI to LSI. Prior data indicate that the mean
response of matched pairs is a 5 mm Hg change in BP
with a standard deviation of 7 mm Hg (unpublished data
from Todd et al. [64]). If the true difference in the mean
response of matched pairs is 5 mmHg, 23 subjects
across both treatments (to give 46 data sets) will be
required to give a power of 90% with error of 0.05.
Accounting for an adjustment factor of 1.56 (drop out of
20%; drop-in of 0%), a total of 37 patients will be
recruited and pass run-in.
Analyses will be undertaken by analysis of covariance
(ANCOVA) adjusting for baseline values using STATA
(Version 12 [65]). To test for time order effects, both the
treatment and treatment order will be included in the
model. If the treatment order is not found to be signifi-
cant, treatment group will be left in the model. Probability
values of < 0.05 will be considered significant. Test for
normality of the distribution of each variable will be per-
formed separately for each treatment group.
Discussion
This trial will provide evidence on the effects of reducing
dietary sodium on cardiovascular risk factors and risk fac-
tors for kidney function decline in participants with mild
to moderate CKD. We anticipate this intervention, a low
sodium intake (60 mmol/day) (compared to usual sodium
intake (180 mmol/day), will result in significant reductions
in 24-hour BP, arterial stiffness, excess fluid and inflamma-
tion, all of which have been shown to be predictors of car-
diovascular abnormalities and/or morbidity and mortality
in CKD patients [3,66,67]. The outcomes of this research
will provide valuable proof-of-concept data for future re-
search in dietary management of CVD risk in CKD, with
the hypothesis being that therapeutic control of sodium
intake will reduce CV disease progression and events in
CKD patients.
A number of potential confounding factors will be
considered in this trial. Potassium intake reduces BP;
therefore changes in potassium intake between the highand low sodium periods may confound the trial results
[68]. As such, participants will be counseled to keep po-
tassium intake stable. In addition potassium intake will
be measured using multiple methods to strengthen val-
idity of the data (24-hour urinary excretion, mid-stream
sodium-to-potassium ratio, diet history). Weight also
directly affects BP [69], so all efforts will be made to
keep weight stable during the 6 week trial and weight
will be measured at all follow up visits as per Figure 2.
GFR may directly affect serum biochemical markers,
therefore estimated GFR (eGFR) will be assessed concur-
rently with other biochemical markers.
There are several attributes to the study design that we
believe will ensure robustness of the results. By employing
the use of sodium chloride tablets versus placebo while
blinding both the participants and the investigators to the
treatment we will be avoiding a confounding effect of
changes in other dietary nutrients, while also reducing risk
of bias. The use of gold standard measurements such as
24-hour BP further strengthens the study. Conducting this
trial in stage III-IV CKD allows us to investigate a strategy
that may potentially delay or prevent adverse outcomes
(such as CVD or ESKD) early in the disease. Furthermore,
we believe the provision of dietary counseling by an accre-
dited practicing dietitian with an individualized approach
will assist dietary adherence. In addition, the multi-method
approach to measuring dietary intake will ensure that diet-
ary adherence will be measured as accurately as possible.
Finally, the long-term follow up will enable us to assess
long-term effects of sodium restriction, whilst also observ-
ing barriers and enablers to dietary adherence that may be
targeted to aid sodium restriction.
Conclusion
The outcomes of this research will provide valuable proof-
of-concept data for a future study of dietary management
of CVD in CKD, with the hypothesis that therapeutic con-
trol of sodium intake will reduce CV disease progression
and events in CKD patients.
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